Could a Cannabis-Derived drug help COPD patients breathe easier?
NCT ID NCT06473701
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether dronabinol, a synthetic form of THC (the psychoactive compound in cannabis), can reduce severe breathlessness in people with advanced COPD. Thirty participants will receive both dronabinol and a placebo in random order to compare effects. The goal is to see if the drug improves daily comfort and activity levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dronabinol (synthetic THC)
- What this could lead to
- If it works, this could offer a new option to ease severe breathlessness in advanced COPD patients who have few other treatments.
- What could go wrong
- This is a small early-phase trial with only 30 people, so results may not apply widely. Dronabinol can cause side effects like dizziness or confusion.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREATHLESSNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vejle Hospital - A part of Lillebaelt Hospital
RECRUITINGVejle, Region Syddanmark, 7100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may curb antibiotic overuse in COPD attacks
- Can pressurized breathing boost mucus clearance in lung disease?
- HIV and hidden health risks: a major study probes the link
- Can tracking early COPD reveal ways to halt its progression?
- Smart inhaler coach: can an app perfect your breathing technique?
- Could everyday supplements shield your lungs?